The most significant change for 2026 will be that the oral antihistamines (OAH) and corticosteroids for intranasal use (INCS) have now been given the strongest recommendation for allergic rhinitis, in contrast to an earlier “conditional” recommendation in the older rules from 2010/2016. This is a result of the revised ARIA-EAACI guidelines that were released in two parts in the journal Allergy, which include intranasal treatments from April 2026, and treatments for ocular or oral allergies in June 2026. In simple terms, doctors now have firmer guidelines based on evidence that tell them what allergy medicines to look for first, and pollen seasons are beginning earlier and lasting longer than in previous years.
What changes have been made in 2026’s guideline for treating allergies?
Three important updates matter the most to patients and healthcare professionals:
- Antihistamines for oral use (OAH) Recommendation updated from conditional to stronger for both perennial and seasonal allergic rhinitis.
- Intranasal corticosteroids (INCS): The treatment has been upgraded to a highly recommended that reinforces INCS as a primary treatment rather than a second-tier alternative.
- Leukotriene receptor antagonists (LTRAs) are now approved for use in seasonal allergy-related rhinitis that is seasonal and are not recommended for the use of LTRAs in chronic allergic rhinitis. This is with a more limited role than previously.
The result is that doctors are more firmly directing patients towards antihistamines as well as nasal steroid sprays as the primary treatment options and leukotriene medications reserved for specific cases.
Why does the allergy season begin sooner in 2026?
The pollen data suggests an earlier and longer time frame, which is mostly due to a warmer season. The peak of pollen in trees is still spring and summer, while grass pollen is peaking in summer and ragweed peaks in the fall; however, the dates for onset have changed earlier, especially on the Gulf Coast and in parts of the Central U.S. Clinicians have reported patients experiencing symptoms for days before the usual time for onset, as well as longer-lasting and more severe symptoms than in the past.
How many people have allergies to the season?
Based on the 2024 CDC National Center for Health Statistics information, about one quarter of U.S. adults and 20 percent of children and teenagers have been diagnosed with a seasonal allergy. The prevalence is highest in the age group 45-65 at 27.7 percent, which is followed by the 65-74 age group (25.5 percent) and those aged 6-11 (25 percent). Adults aged 18-44 are at 24.3 percent, teenagers 12–17 are at 24% and adult older than 75 are at 21.7 percent, and kids younger than 5 years old are at 11.6 percent.
Seasonal Allergy Guidelines 2026: What Can You Do to Manage the Symptoms
Start intranasal corticosteroids early. Start 2-4 weeks prior to the typical date of onset of symptoms and not until symptoms begin.
- Combine it with an oral antihistamine in the event that the nasal symptoms by themselves aren’t enough to control. The combination currently has a solid guideline to support.
- Check local pollen counts, and adjust your activity and medication timing to coincide with days with high levels of pollen.
- Close windows in peak pollen time (typically the early morning hours) instead of airing the home.
- Wash and change your clothes following exposure to the outdoors to get rid of pollen before it gets into the indoor environment or causes symptoms at night.
- Be aware of sleep disturbances. The postnasal drip that is caused by allergic rhinitis is more often connected to sleep disturbances and fatigue the next day — signal this to your healthcare provider instead of thinking it is unrelated.
- Check if you’re in need of regular treatment. Clinicians are receiving more patients who experienced mild symptoms on occasion, but now require consistent, year-round treatment.
Does the access to epinephrine change too?
Yes. In March 2026, the FDA eliminated the age limit to use the one-milligram dose of epinephrine in the spray for nasal use (Neffy) and changed the eligibility criteria to a weight-based cutoff of 33 pounds or more, no matter the age. This is particularly relevant to allergy sufferers who carry epinephrine as an anaphylaxis risk, as well as expanding the option of a needle-free spray to children younger than the weight limit.
Conclusion
Guidelines change every few years, but access to care should not depend on how far you live from a specialist. Telemedicine Alaska has bridged that gap to become a trusted telemedicine provider, connecting patients in Anchorage, Fairbanks, Juneau, and remote communities with licensed clinicians who are up-to-date on changes to the Seasonal Allergy Guidelines 2026, such as the 2026 ARIA-EAACI guidelines. Starting intranasal corticosteroids before pollen season, changing up an antihistamine routine, or getting a same-week virtual consult instead of waiting months for an in-person allergist — Telemedicine Alaska provides Alaskans a reliable, evidence-based way to treat seasonal allergies without the long drive. Where distance is often the biggest barrier to care, that reliability makes Telemedicine Alaska a trusted name in telemedicine throughout the state.
